Relmada Therapeutics (STU:4E2) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4E2 Relmada Therapeutics Inc STU:4E2
29 GF Score
Price €3.58
! 2 Warning Signs
View Full Analysis

What is Relmada Therapeutics Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:4E2
29GF Score
Relmada Therapeutics Inc STU:4E2
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relmada Therapeutics Business Description

Other Exchanges RLMD:USA
Address 2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc. is a clinical-stage biopharmaceutical company based in the United States that develops therapies for central nervous system disorders and other serious conditions. Its pipeline has centered on esmethadone (REL-1017), an NMDA receptor channel blocker being developed as an oral adjunctive treatment for major depressive disorder, along with earlier-stage programs. The company has also pursued NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and sepranolone, a neurosteroid being explored for conditions linked to excessive GABAergic activity such as Prader-Willi syndrome and Tourette syndrome. As a clinical-stage company, Relmada has no approved products and generates no product revenue; it funds operations primarily through equity financings and capital markets activity. Its activities are concentrated in the United States, with clinical trials conducted domestically and internationally.
29GF Score

Get the complete analysis for STU:4E2

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.58
Price